Close
Help




JOURNAL

Biomarkers in Cancer

Biomarkers and Targeted Therapy in Pancreatic Cancer

Submit a Paper


Biomarkers in Cancer 2016:Suppl. 1 27-35

Review

Published on 26 Apr 2016

DOI: 10.4137/BIC.S34414


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract

Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Considering that pancreatic cancer shows early invasion and metastasis, critical research is needed to explore different aspects of the disease, such as elaboration of biomarkers, specific signaling pathways, and gene aberration. In this review, we highlight the biomarkers, the fundamental signaling pathways, and their importance in targeted drug delivery for pancreatic cancers.



Downloads

PDF  (1.18 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




Quick Links


New article and journal news notification services